Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia
- 1 May 1994
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 24 (5), 1167-1171
- https://doi.org/10.1002/eji.1830240524
Abstract
Interleukin‐10 (IL‐10) is a potent inhibitor of lipopolysaccharide (LPS)‐induced tumor necrosis factor (TNF) production and has been shown to protect mice from endotoxin shock. As IFN‐γ is another important mediator of LPS toxicity, we studied the effects of IL‐10 on LPS‐induced IFN‐γ synthesis in vitro and in vivo. First, we found that the addition of recombinant human IL‐10 (rhIL‐10) (10 U/ml) to human whole blood markedly suppressed LPS‐induced IFN‐γ release while neutralization of endogenously synthesized IL‐10 resulted in increased IFN‐γ levels. The ability of rIL‐10 to inhibit LPS‐induced IFN‐γ synthesis was also observed in vivo in mice. Indeed, administration of 1000 U recombinant mouse IL‐10 (rmIL‐10) 30 min before and 3 h after challenge of BALB/c mice with 100 μg LPS resulted in a threefold decrease in peak IFN‐γ serum levels. We then examined the production and the role of IL‐10 during murine endotoxemia. We found that LPS injection causes the rapid release of IL‐10, peak IL‐10 serum levels being observed 90 min after LPS challenge. Neutralization of endogenously produced IL‐10 by administration of 2 mg JES5‐2A5 anti‐IL‐10 monoclonal antibody (mAb) 2h before LPS challenge resulted in a marked increase in both TNF and IFN‐γ serum levels while irrelevant isotype‐matched mAb had no effect. The enhanced production of inflammatory cytokines in anti‐IL‐10 mAb‐treated mice was associated with a 60% lethality after injection of 500 μg LPS, while all mice pretreated with control mAb survived. We conclude that the rapid release of IL‐10 during endotoxemia is a natural antiinflammatory response controlling cytokine production and LPS toxicity.Keywords
This publication has 27 references indexed in Scilit:
- Modified Immunological Status of Anti-IL-10 Treated MiceCellular Immunology, 1993
- In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A.The Journal of Experimental Medicine, 1993
- Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.The Journal of Experimental Medicine, 1993
- Interferon gamma inhibits interleukin 10 production by monocytes.The Journal of Experimental Medicine, 1993
- Role of Interferon- in Experimental Gram-Negative SepsisThe Journal of Infectious Diseases, 1992
- Macrophage deactivation by interleukin 10.The Journal of Experimental Medicine, 1991
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.The Journal of Experimental Medicine, 1991
- The role of IL-10 in crossregulation of TH1 and TH2 responsesImmunology Today, 1991
- Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10International Immunology, 1990
- Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.Journal of Clinical Investigation, 1988